Summary: Comparative immune response profiling is important for selecting next-generation vaccines. We comprehensively evaluated the antibody responses from a panel of nine respiratory vaccines against Ebola virus (EBOV) derived from human and avian paramyxoviruses expressing EBOV glycoprotein (GP). Most vaccines were protective in guinea pigs but yielded antibody repertoires that differed in proportion targeting key antigenic regions, avidity, neutralizing antibody specificities, and linear epitope preferences. Competition studies with monoclonal antibodies from human survivors revealed that some epitopes in GP targeted for neutralization were vector dependent, while EBOV-neutralizing titers correlated with the response magnitude toward th...
Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emer...
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that...
Introduction: Identifying immune correlates of protection is a priority for malaria vaccine research...
Summary: We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated wit...
International audienceOBJECTIVES: For Ebola vaccine development, antibody response is a major endpoi...
and>10 000 deaths. There are 5 genetically and antigenically distinct species within the genus Eb...
Summary: Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RB...
Ebola virus disease is a deadly infection which occurs in sporadic outbreaks. Several vaccine candid...
As the most advanced Ebola virus vaccine candidate, recombinant vesicular stomatitis virus–Zaire Ebo...
SummaryPrevious efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS)...
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombi...
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies h...
This thesis describes an analysis of the B cell repertoire in humans in response to infection or vac...
Ebola virus (EBOV) represents a major concern to global health due to the unpredictable nature of ou...
<div><p>We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform b...
Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emer...
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that...
Introduction: Identifying immune correlates of protection is a priority for malaria vaccine research...
Summary: We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated wit...
International audienceOBJECTIVES: For Ebola vaccine development, antibody response is a major endpoi...
and>10 000 deaths. There are 5 genetically and antigenically distinct species within the genus Eb...
Summary: Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RB...
Ebola virus disease is a deadly infection which occurs in sporadic outbreaks. Several vaccine candid...
As the most advanced Ebola virus vaccine candidate, recombinant vesicular stomatitis virus–Zaire Ebo...
SummaryPrevious efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS)...
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombi...
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies h...
This thesis describes an analysis of the B cell repertoire in humans in response to infection or vac...
Ebola virus (EBOV) represents a major concern to global health due to the unpredictable nature of ou...
<div><p>We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform b...
Ebolaviruses pose significant public health problems due to their high lethality, unpredictable emer...
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that...
Introduction: Identifying immune correlates of protection is a priority for malaria vaccine research...